External validation of dementia prediction models in Black or African American and White older adults: A longitudinal population‐based study in the United States

Utilizing risk-prediction models to identify individuals at higher risk of Alzheimer's disease (AD) dementia could benefit clinicians, patients, and policymakers. Clinicians could enroll high-risk individuals in clinical trials to test new risk-modifiable treatments or initiate lifestyle modifications, which, if successful, would slow cognitive decline and delay the onset of the disease. Current risk-prediction models had good discriminative power during the first 6 years of follow-up but decreased with longer follow-up time. Acknowledging the longer preclinical phase of AD dementia development and racial differences in dementia risk, there is a need to develop race-specific risk-prediction models that can predict 10 or 20 years of risk for AD and related dementias.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2024-10-12
DOI
https://doi.org/10.1002/alz.14280
Citations
6
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
2.31

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

External validation of dementia prediction models in Black or African American and White older adults: A longitudinal population‐based study in the United States

Ted Kheng Siang Ng, Pankaja Desai, Lisa L. Barnes, Kumar B. Rajan et al.
6 citations
Alzheimer s & Dementia
Dementia and Cognitive Impairment Research
2.31
article

External validation of dementia prediction models in Black or African American and White older adults: A longitudinal population‐based study in the United States

Ted Kheng Siang Ng, Pankaja Desai, Lisa L. Barnes, Kumar B. Rajan, Todd Beck, Denis A. Evans, Anisa Dhana, Klodian Dhana, Xiaoran Liu
article en
6 citations

Abstract

Utilizing risk-prediction models to identify individuals at higher risk of Alzheimer's disease (AD) dementia could benefit clinicians, patients, and policymakers. Clinicians could enroll high-risk individuals in clinical trials to test new risk-modifiable treatments or initiate lifestyle modifications, which, if successful, would slow cognitive decline and delay the onset of the disease. Current risk-prediction models had good discriminative power during the first 6 years of follow-up but decreased with longer follow-up time. Acknowledging the longer preclinical phase of AD dementia development and racial differences in dementia risk, there is a need to develop race-specific risk-prediction models that can predict 10 or 20 years of risk for AD and related dementias.

Alzheimer s & DementiaVol. 20(11)
Rush University Medical Center (US)
Alzheimer's Association, National Institutes of Health, National Institute on Aging
Reduced inequalities
Openalex Percentile: Top 11%
Dementia and Cognitive Impairment Research
2.31
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.